Europeiska unionen - svenska - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - bröst-neoplasmer - antineoplastiska medel - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - pazopanibhydroklorid - filmdragerad tablett - 200 mg - pazopanibhydroklorid 216,7 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - pazopanibhydroklorid - filmdragerad tablett - 400 mg - pazopanibhydroklorid 433,4 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastiska medel - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.